CryoLife today announced that it is rebranding itself and changing its name to Artivion, effective immediately.
The Kennesaw, Georgia-based company’s new name, derived from the words ‘aorta,’ ‘innovation’ and ‘vision,’ reflects its focus on creating devices to treat aortic disease. The company will also change its ticker symbol on the New York Stock Exchange to ‘AORT’ on January 24.
“Through a combination of legacy products and strategic acquisitions and divestitures over the last five years, we have transformed from a tissue and adhesives focused company to one with a premier portfolio of aortic products,” CEO and president Pat Mackin said in a news release. “Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons’ most difficult clinical challenges in treating patients with aortic disease.”
CryoLife was founded in 1984 in Georgia but has since expanded with offices in Austin, Texas, the U.K., Germany and Singapore. Shares in CRY were at a standstill before the market opened.
